Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Maveropepimut-S (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Fallopian tube cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Keynote903
  • Sponsors IMV

    • Most Recent Events

    • 13 May 2022 According to an IMV media release, preliminary data was presented at the 2022 American Association of Cancer Research (AACR) annual meeting.
    • 13 Apr 2022 Preliminary Results (n=17) assessing safety efficacy and pharmacodynamic, presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 08 Apr 2022 Preliminary Results published in the IMV Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top